(2015 -present)：
1.Yuan Pei#, Jingfeng Fu#, Yunkai Shi#, Mengmeng Zhang, Guanghao Luo, Xiaomin Luo, Ning Song, Tian Mi, Yaxi Yang, Jia Li,* Yubo Zhou,* Bing Zhou*， Discovery of a Potent and Selective Degrader for USP7, Angew. Chem. Int. Ed., 2022, 61, e202204395.
2.Xiangbo Yang#, Huimin Lu#, Hang Xie#, Binbin Zhang, Tianqing Nie, Chen Fan, Tao Yang, Yechun Xu, Haixia Su,* Wei Tang,* and Bing Zhou*. Potent and Selective RIPK1 Inhibitors Targeting Dual-Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis. Angew. Chem. Int. Ed., 2022, 61, e202114922.
3.Jing Niu#, Hudagula Bai #, Zizhou Li, Yuzhe Gao, Yan Zhang, Xiyuan Wang,Yaxi Yang, Yungen Xu,* Meiyu Geng, Zuoquan Xie,* Bing Zhou,* Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration, European Journal of Medicinal Chemistry, 2022, 238, 114482.
4.Liping Liao, Wenzhen Dang, Tingting Lin, Jinghua Yu, Tonghai Liu, Wen Li, Senhao Xiao, Lei Feng, Jing Huang, Rong Fu, Jiacheng Li, Liping Liu, Mingchen Wang, Hongru Tao, Hualiang Jiang, Kaixian Chen, Xingxing Diao, Bing Zhou*, Xiaoyan Shen*, Cheng Luo*. A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1b and IL-6. Acta Pharm. Sin. B, 2022, in press.
5.Qilong Tan, Ziqun Liu, Xiaobo Gao, Yibo Wang, Xuefeng Qiu, Jiahui Chen, Liuchun Liang, Hongqian Guo, Shengsong Huang, Denglong Wu, Bing Zhou*, Ronggui Hu* and Zhenfei Li*. Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors. Oncogene, 2022, in press.
6.Wenwen Yu,# Chao Chen, # Lei Feng, Tianqi Xia, Chen Shi, Yaxi Yang,* and Bing Zhou*. Rhodium(III)-Catalyzed Asymmetric 1,2-Carboamidation of Alkenes Enables Access to Chiral 2,3-Dihydro-3-benzofuranmethanamides. Org. Lett. 2022, 24, 1762-1767.
7.Jiaqi Jiang#, Junli Yang#, Siqi Li#, Yaxi Yang,* and Bing Zhou* Ruthenium(II)-Catalyzed ortho Hydroxymethylation of 6-Arylpurines with Paraformaldehyde via Purine-Directed C-H Activation, Heterocycles, 2022, 104(10), 1792-1808
8.Chenxing Ji#, Wen Xu#, Hong Ding#, Zhengyuan Chen#, Chengzhang Shi, Jie Han, Liang Yu, Nidan Qiao, Yichao Zhang, Xiaoyun Cao, Xiang Zhou, Haixia Cheng, Huijin Feng, Cheng Luo, Zhiyu Li*, Bing Zhou*, Zhao Ye* and Yao Zhao. The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma. J Clin Endocrinol Metab, 2022, 107, e2291-e2300.
9.Shijie Fan#, Liyan Yue#, Wei Wan#, Yuanyuan Zhang#, Bidong Zhang#, Chinatsu Otomo, Quanfu Li, Tingting Lin, Junchi Hu, Pan Xu, Mingrui Zhu, Hongru Tao, Zhifeng Chen, Lianchun Li, Hong Ding, Zhiyi Yao, Junyan Lu, Yi Wen, Naixia Zhang, Minjia Tan, Kaixian Chen, Yuli Xie, Takanori Otomo, Bing Zhou*, Hualiang Jiang*, Yongjun Dang*, and Cheng Luo*. Inhibition of autophagy by a small molecule through covalent modification of LC3. Angew. Chem. Int. Ed. 2021, 60 (50), 26105-26114.
10.Tian Lu#, Yong Li#, Wenchao Lu#, T.W.G.M. Spitters#, Xueyu Fang, Jun Wang, Simian Cai, Jing Gao, Yanting Zhou, Zhe Duan, Huan Xion, Liping Liu, Qi Li, Hualiang Jiang, Kaixian Chen, Hu Zhou, Hua Lin, Huijin Feng, Bing Zhou*, Christopher L. Antos*, Cheng Luo*. Acta Pharmaceutica Sinica B, 2021, 11 (10), 3206-3219.
11.Yunkai Shi, Chao Chen, Yaxi Yang, Bing Zhou.* Rh(III)-catalyzed selective C7-H functionalization of indolines with 1,3-enynes enables access to six-membered 1,7-fused indolines. Tetrahedron Lett 2021, 72, 153065.
12.Xiangbo Yang#, Zhijia Wang#, Yuan Pei, Ning Song, Lei Xu, Bo Feng, Hanlin Wang, Xiaomin Luo, Xiaobei Hu, Xiaohui Qiu, Huijin Feng, Yaxi Yang, Yubo Zhou*, Jia Li*, Bing Zhou*. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. Eur. J. Med. Chem. 2021, 218, 113341.
13.Tingting Lin, Jiacheng Li, Liping Liu, Yuanqing Li, Hualiang Jiang, Kaixian Chen, Pan Xu, Cheng Luo, Bing Zhou*. Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors. Eur J Med Chem 2021, 215, 113281.
14.Jian Lin, Liuyu Hu, Chao Chen, Huijin Feng, Yang Yu,* Yaxi Yang,* and Bing Zhou.* Rhodium-Catalyzed Twofold Unsymmetrical C-H Alkenylation-Annulation/Thiolation Reaction To Access Thiobenzofurans. Org. Lett. 2021, 23, 4, 1194-1198.
15.Chao Chen#, Shi Chen#, Yaxi Yang, Bing Zhou.* Rh(III)-catalyzed tandem annulative redox-neutral arylation/amidation of aromatic tethered alkenes. Chemical Science, 2020, 11, 44, 12124-12129.
16.Siqi Li, Yang Yu,* Yaxi Yang, and Bing Zhou.* Ruthenium(II)-Catalyzed Regioselective C-H Hydroxymethylation of N-Aryl-azaindoles with Paraformaldehyde. Heterocycles 2020, 100 (6), 934-945.
17.Yaxi Yang, Rukang Zhang, Zhaojun Li, Lianghe Mei, Shili Wan, Hong Ding, Zhifeng Chen, Jing Xing, Huijin Feng, Jie Han, Hualiang Jiang, Mingyue Zheng,*Cheng Luo,* Bing Zhou.* Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors. J. Med. Chem. 2020, 63, 1337.
18.Zizhou Li, Senhao Xiao, Yaxi Yang, Chao Chen, Tian Lu, Zhifeng Chen, Hualiang Jiang, Shijie Chen, Cheng Luo,* and Bing Zhou.* Discovery of 8-Methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Highly Potent and Selective Bromodomain and Extra-terminal (BET) Bromodomain Inhibitors. J. Med. Chem., 2020, 63, 8, 3956-3975.
19.Yanni Chen, Liuyu Hu, Liuchun Liang, Fujiang Guo,Yaxi Yang, Bing Zhou* Ruthenium(II)-Catalyzed Regioselective Ortho C–H Allenylation of Electron-Rich Aniline and Phenol Derivatives. J. Org. Chem. 2020, 85, 4, 2048.
20.Yu Chen, Xiaoyang Bi, Fengcai Zhang, Zhongya Suna, Pan Xu, Hao Jiang, Wenchao Lu, Tian Lu, Hong Ding, Naixia Zhang, Hualiang Jiang, Kaixian Chen, Bing Zhou,* Cheng Luo* Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain. Bioorg. Chem., 2020, 101, 103991.
21.Xiaoyang Bi, Yu Chen, Zhongya Sun, Wenchao Lu, Pan Xu, Tian Lu, Hong Ding, Naixia Zhang, Hualiang Jiang, Kaixian Chen, Bing Zhou,* Cheng Luo* Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors. Bioorg. Med. Chem. Lett., 2020, 30, 127480.
22.Chengzhang Shi, Zhao Ye, Jie Han, Xiaoqing Ye, Wenchao Lu, Chenxing Ji, Zizhou Li, Zengyi Ma, Qilin Zhang, Yichao Zhang, Wenqiang He, Zhengyuan Chen, Xiaoyun Cao, Xuefei Shou, Xiang Zhou, Yongfei Wang, Zhaoyun Zhang , Yiming Li, Hongying Ye, Min He, Hong Chen, Haixia Cheng, Jun Sun, Jianyong Cai, Chuanxin Huang, Fei Ye, Cheng Luo, Bing Zhou, Hong Ding,* and Yao Zhao* BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma. Neuro-Oncology, 2020, 22, 1114–1125.
23.Yunxiang Wu, Zhaoqiang Chen, Yaxi Yang, Weiliang Zhu,* Bing Zhou.* Rh(III)-Catalyzed Redox-Neutral Unsymmetrical C-H Alkylation and Amidation Reactions of N-Phenoxyacetamides. J. Am. Chem. Soc., 2018, 140, 42.
24.Wenchao Lu, Jun Wang, Yong Li, Hongru Tao, Huan Xiong, Fulin Lian, Jing Gao, Hongna Ma, Tian Lu, Dan Zhang, Xiaoqing Ye, Hong Ding, Liyan Yue, Yuanyuan Zhang, Huanyu Tang, Naixia Zhang, Yaxi Yang, Hualiang Jiang, Kaixian Chen, Bing Zhou,* Cheng Luo.* Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors. Eur. J. Med. Chem., 2019, 184, 111767.
25.Bing Zhou, Jiantao Hu, Fuming Xu, Zhuo Chen, Longchuan Bai, Ester Fernandez-Salas, Mei Lin, Liu Liu, Chao-Yie Yang, Yujun Zhao, Donna McEachern, Sally Przybranowski, Bo Wen, Duxin Sun, and Shaomeng Wang* Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression J. Med. Chem. 2018, 61, 462.
26.Yujun Zhao, # Bing Zhou (co-first author), # Longchuan Bai, Liu Liu, Chao-Yie Yang, Jennifer L. Meagher, Jeanne A. Stuckey, Donna McEachern, Sally Przybranowski, Mi Wang, Xu Ran, Angelo Aguilar, Yang Hu, Jeff W. Kampf, Xiaoqin Li, Ting Zhao, Siwei Li, Bo Wen, Duxin Sun, and Shaomeng Wang.* Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. J. Med. Chem., 2018, 61, 6110？6120.
27.Huan Xiong, Jie Han, Jun Wang, Wenchao Lu, Chen Wang, Yu Chen, Fulin Lian, Naixia Zhang, Yu-Chih Liu, Chenhua Zhang, Hong Ding, Hualiang Jiang, Wencong Lu, Cheng Luo,* Bing Zhou.* Discovery of 1,8-acridinedione derivatives as novel GCN5 inhibitors via high throughput screening. Eur. J. Med. Chem., 2018, 151, 740-751.
28.Chong Qin,# Yang Hu,# Bing Zhou (co-first author),# Ester Fernandez-Salas, Chao-Yie Yang, Liu Liu, Donna McEachern, Sally Przybranowski, Mi Wang, Jeanne Stuckey, Jennifer Meaghe, Longchuan Bai, Zhuo Chen, Mei Lin, Jiuling Yang, Danya N. Ziazadeh, Fuming Xu, Jiantao Hu, Weiguo Xiang, Liyue Huang, Siwei Li, Bo Wen, Duxin Sun, and Shaomeng Wang*. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J. Med. Chem., 2018, 61, 6685–6704.
29.Wenchao Lu, Huan Xiong, Yu Chen, Chen Wang, Hao Zhang, Pan Xu, Jie Han, Senhao Xiao, Hong Ding, Zhifeng Chen, Tian Lu, Jun Wang, Yuanyuan Zhang, Liyan Yue, Yu-Chih Liu, Chenhua Zhang, Yaxi Yang, Hualiang Jiang, Kaixian Chen, Bing Zhou,* Cheng Luo.* Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors. Bioorg. Med. Chem., 2018, 26, 5397–5407.
30.Yubo Wang, Yu Chen,* Yaxi Yang and Bing Zhou.* A Rh(III)-catalyzed redox-neutral C–H alkylation reaction with allylic alcohols by using a traceless oxidizing directing group. Org. Chem. Front., 2018, 5, 1844–1847.
31.Haibin Zhou, Weihua Zhou, Bing Zhou, Liu Liu, Ting-Rong Chern, Krishnapriya Chinnaswamy, Jianfeng Lu, Denzil Bernard, Chao-Yie Yang, Shasha Li, Mi Wang, Jeanne Stuckey, Yi Sun, and Shaomeng Wang.* High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein–Protein Interaction. J. Med. Chem., 2018, 61, 1934–1950.
32.Mengying Gao, Yaxi Yang, Hua Chen,* Bing Zhou.* Rhodium-Catalyzed C？H Functionalization of Indoles with Diazo Compounds: Synthesis of Structurally Diverse 2,3-Fused Indoles. Adv. Synth. Catal., 2018, 360, 100–105.
33.Longchuan Bai,# Bing Zhou (co-first author),# Chao-Yie Yang, Jiao Ji, Donna McEachern, Sally Przybranowski, Hui Jiang, Jiantao Hu, Fuming Xu, Yujun Zhao, Liu Liu, Ester Fernandez-Salas, Jing Xu, Yali Dou, Bo Wen, Duxin Sun, Jennifer Meagher, Jeanne Stuckey, Daniel F. Hayes, Shunqiang Li, Matthew J. Ellis and Shaomeng Wang.* Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res. 2017, 77, 2476-2487.
34.Yunxiang Wu, Bing Zhou*. Ruthenium-Catalyzed Direct Hydroxymethylation of Aryl C–H Bonds. ACS Catal., 2017, 7 , 2213.
35.Yunxiang Wu, Bing Zhou.* Rhodium(III)-Catalyzed Selective C–H Acetoxylation and Hydroxylation Reactions. Org. Lett., 2017, 19, 3532–3535.
36.Wei Hou, Yaxi Yang, Yunxiang Wu, Huijin Feng, Yuanchao Li and Bing Zhou,* Rhodium(III)-catalyzed alkylation of primary C(sp3)–H bonds with -diazocarbonyl compounds. Chem. Commun., 2016, 52, 9672-9675.
37.Liyan Yue, Juanjuan Du, Fei Ye, Zhifeng Chen, Lianchun Li, Fulin Lian, Bidong Zhang, Yuanyuan Zhang,* Hualiang Jiang, Kaixian Chen, Yuanchao Li, Bing Zhou, Naixia Zhang, Yaxi Yang* and Cheng Luo.* Identification of novel small-molecule inhibitors targeting menin–MLL interaction, repurposing the antidiarrheal loperamide. Org. Biomol. Chem., 2016, 14, 8503–8519
38.Wen Ai, Yunxiang Wu, Huanyu Tang, Xueyan Yang, Yaxi Yang,* Yuanchao Li and Bing Zhou.* Rh(III)- or Ir(III)-catalyzed ynone synthesis from aldehydes via chelation-assisted C–H bond activation. Chem. Commun., 2015, 51, 7871-7874.
39.Wei Hou, Yaxi Yang, Wen Ai, Yunxiang Wu, Xuan Wang, Bing Zhou,* Yuanchao Li.* IrIII-Catalyzed Direct C-7 Amidation of Indolines with Sulfonyl, Acyl, and Aryl Azides at Room Temperature. Eur. J. Org. Chem., 2015, 395–400.
40.Xu Ran, Yujun Zhao, Liu Liu, Longchuan Bai, Chao-Yie Yang, Bing Zhou, Jennifer L. Meagher, Krishnapriya Chinnaswamy, Jeanne A. Stuckey, and Shaomeng Wang* Structure-Based Design of ？Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. J. Med. Chem., 2015, 58, 4927？4939
41.Yunxiang Wu , Yaxi Yang , Bing Zhou,* and Yuanchao Li.* Iridium(III)-Catalyzed C-7 Selective C–H Alkynylation of Indolines at Room Temperature. J. Org. Chem., 2015, 80, 1946–1951.
42.Xuan Wang , Huanyu Tang , Huijin Feng , Yuanchao Li *, Yaxi Yang *, and Bing Zhou.* Access to Six- and Seven-Membered 1,7-Fused Indolines via Rh(III)-Catalyzed Redox-Neutral C7-Selective C–H Functionalization of Indolines with Alkynes and Alkenes. J. Org. Chem., 2015, 80, 6238–6249.
43.Yaxi Yang, Xuan Wang, Yuanchao Li, and Bing Zhou* A [4+1] Cyclative Capture Approach to 3H-Indole-N-oxides at Room Temperature by Rhodium(III)-Catalyzed C-H Activation. Angew. Chem. Int. Ed. 2015, 54, 15400-15404.
44.Bing Zhou,* Zhaoqiang Chen, Yaxi Yang,* Wen Ai, Huanyu Tang, Yunxiang Wu, Weiliang Zhu,* Yuanchao Li. Rhodium-Catalyzed Redox-Neutral C-H Functionalization of Arylamine N-Oxides with Diazo Compounds: Primary C(sp3)-H/C(sp2)-H Activation and Oxygen Atom Transfer. Angew. Chem. Int. Ed. 2015, 54, 12121-12126.
研究生教育
药物所首页
